FDA licensure of bivalent human papillomavirus vaccine (HPV2, cervarix) for use in females and updated HPV vaccination recommendations from the advisory committee on immunization practices (ACIP)

Morbidity and Mortality Weekly Report

Volumn 59, Issue 20, 2010, Pages 626-629

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; CHILD; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; IMMUNOLOGY; LICENSING; PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; UTERINE CERVIX TUMOR;

ADOLESCENT; ADULT; ANTIBODY FORMATION; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION SCHEDULE; LICENSURE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77953080981     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CDC. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-2).
2. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009;2:868-78.
3. Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck & Co, Inc: Food and Drug Administration 2009. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm094042.htm. Accessed May 25, 2010.
4. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14.
5. Food and Drug Administration. Product approval-prescribing information [package insert]. Cervarix [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant], GlaxoSmithKline Biologicals: Food and Drug Administration 2009. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm186957.htm. Accessed May 25, 2010.
6. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
7. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85.
8. Wheeler CM. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine co-administered with other vaccines in female adolescents [Abstract]. Presented at the 47th annual meeting of the Infectious Diseases Society of America, Philadelphia, PA, October 29-November 1, 2009.
9. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-40.
10. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8.